Investors

Corporate Profile

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, the Company is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.

| (Common Stock)

Stock chart for: SBBP.O. Currently trading at $4.40 with a 52 week high of $6.24 and a 52 week low of $2.00.

Data provided by Nasdaq. Minimum 15 minutes delayed.

Press Releases

Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares

08/14/18

DUBLIN, Ireland and TREVOSE, Pa. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that it intends to offer and sell 9,000,000 of its ordinary shares in an underwritten public offering. The Company also intends to grant the underwriters a
...

Read More
Strongbridge Biopharma plc Reports Second Quarter 2018 Financial Results and Provides Corporate Update

08/08/18

~ Statistically Significant Positive Top-line Clinical Results Reported from SONICS Phase 3 Study of RECORLEV™ (levoketoconazole) in Endogenous Cushing's Syndrome ~ ~ Rare Endocrine Franchise Expands with the U.S. Launch of MACRILEN ™ (macimorelin) for the Diagnosis of Adult Growth Hormone
...

Read More

Investors

Investors

Corporate Profile

Press Releases

Strongbridge Biopharma plc Announces Proposed Public Offering of Ordinary Shares

Strongbridge Biopharma plc Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Upcoming Events